Lv2
130 积分 2026-09-13 加入
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
19小时前
待确认
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
19小时前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
5天前
已完结
Balancing remission durability and treatment burden in older acute myeloid leukemia. Comment on: "Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia"
8天前
已完结
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia
8天前
已完结
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort
13天前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
13天前
已完结
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
1个月前
已完结
Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study
1个月前
已完结
皖公网安备34019202002308
